Angiogenesis Inhibitor GT-111

An adenovirus encoding an endothelial cell-specific, murine pre-proendothelin-1 (PPE-1) promoter and a Fas-based chimeric death receptor with potential anti-angiogenic activity. Endothelial cell-specific transcriptional control of the adenoviral vector is achieved by the use of a modified murine PPE-1 promoter that is specifically activated in PPE-1-expressing angiogenic endothelial cells residing in the tumor microvasculature. Subsequently, the Fas-c (Fas-chimeric) death receptor, containing Fas and tumor necrosis factor (TNF) receptor 1 (TNFR1) moieties, is expressed in angiogenic endothelial cells; endothelial cell-specific Fas-mediated apoptosis is initiated by the binding of TNF-alpha, abundant in the tumor microenvironment, to the TNFR1 moiety of the expressed Fas-c death receptor. (NCI Thesaurus)

YOU MAY ALSO LIKE

Angiogenesis inhibitor

A drug or substance that keeps new blood vessels from forming. In cancer treatment, angiogenesis inhibitors may prevent the growth of new…

Angiogenesis Activator Inhibitor

An angiogenesis inhibitor that acts by blocking the action of endogenous pro-angiogenic substance(s).

Angiogenesis

Blood vessel formation. Tumor angiogenesis is the growth of new blood vessels that tumors need to grow. This process is caused by…

Angiofollicular Lymphoid Hyperplasia

A disorder characterized by lymphoid hyperplasia in the lymph nodes. There are two histologic variants recognized: the hyaline-vascular type and the plasma…

Angiofollicular lymph node hyperplasia

A rare disorder in which benign (not cancer) growths form in lymph node tissue. There are two main ways that angiofollicular lymph…

Angiofibroma

A morphologic variant of fibroma characterized by the presence of numerous dilated vascular channels.